Jan 20: Bill Clinton's second inaugural. Michael Marco and Mark Harrington finish initial draft of OI Report. Jan 22: Crisis at Retrovirus re: on-site registration for Linda Grinberg and sixteen other unregistered community members. They are not allowed in. (Relations…
Overwhelming Array of Variables Confounds Interpretation of Co-Infection Studies Answers Not Forthcoming Estimates of HCV prevalence among people with HIV in the United States range from 30% to 50%, with even higher rates among people infected through injection drug use…
End Stage Liver Disease Emerges As Leading Cause of Death in PWAs with Hepatitis C “While many people with HIV are living longer, more productive lives,” Michael Marco explains,” a good many who are also co-infected with the hepatitis C…
August 2000 Striking Lack of Awareness "People with hepatitis C infection deserve the same tools as those with HIV so that they can become experts about their virus," explains Michael Marco in the introduction to TAG's latest analysis of hepatitis…
August 2000 by Michael Marco and Jeffrey Schouten The CDC should further investigate the role of HCV sexual transmission in men who have sex with men. The CDC should update its 1998 HCV recommendations to suggest HCV testing for all…
Progress Is Being Made But Much Remains to Be Done in the Treatment of Hepatitis C Infection June 2000 Sexual Transmission Controversy Michael Marco, TAG's Infections and Oncology Project Director, had his plate full in San Francisco this past February…
Merck’s Cavalier Attitude Toward the Welfare of HIV/HCV-Coinfected Patients by Tracy Swan In places where access to antiretroviral therapy is widespread, people living with HIV are now dying from a common and curable coinfection: hepatitis C virus (HCV). HIV increases…
TAG at 20: Early Campaigns; The Odyssey of Therapeutic Vaccines for HIV; What You Don’t Know, You Can Sell; Does Obama’s 2013 Budget Herald the End of PEPFAR?; Childhood TB Advocacy Picks Up Steam
The Hepatitis C Community Advisory Board (HCAB) recognizes the value of more effective and less toxic treatment for hepatitis C virus (HCV).
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.